Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
Publishing timestamp: 2024-02-06 12:06:01
Summary
Eli Lilly's drug tirzepatide has shown promise as a treatment for fatty liver disease in a mid-stage trial. The drug, which is already used for weight loss and diabetes, has potential health benefits beyond its current uses. The trial results showed that tirzepatide helped patients shed pounds and regulate blood sugar, and it also showed positive results in treating a serious form of liver disease called MASH. This could potentially expand insurance coverage for weight loss drugs. The drug met the trial's main goal of helping patients become free of disease with no worsening of liver scarring. The reduction of liver scarring was also considered clinically meaningful. Eli Lilly is encouraged by the results and plans to move forward with phase three trials. Other drugmakers are also developing treatments for MASH.
Sentiment: POSITIVE
Keywords: breaking news, biotechnology, pharmaceuticals, health care industry, business news, biotech and pharmaceuticals, business, science, novo nordisk a/s, eli lilly and co,
Source: https://www.cnbc.com/2024/02/06/eli-lilly-weight-loss-drug-may-treat-fatty-liver-disease.html